Dramatic improvement of DC-based immunotherapy against various malignancies

Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacie...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioscience Vol. 16; no. 6; p. 2233
Main Authors Harada, Yui, Yonemitsu, Yoshikazu
Format Journal Article
LanguageEnglish
Published Singapore 01.06.2011
Subjects
Animals
Cancer Vaccines - administration & dosage
Cancer Vaccines - therapeutic use
Cells, Cultured
Dendritic Cells - immunology
Dose-Response Relationship, Immunologic
Humans
Immunotherapy, Adoptive - methods
Immunotherapy, Adoptive - trends
Melanoma, Experimental - immunology
Melanoma, Experimental - therapy
Mice
Models, Immunological
Neoplasms - immunology
Neoplasms - therapy
Online AccessGet full text

Cover

More Information
Summary:Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible breakthrough, a simple cytokine-based culture method to realize a log-scale order of functional murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deficient recombinant Sendai virus (rSeV) were dramatically more effective than that seen in the use of current DC vaccine for immunotherapy against malignancies. Our study could overcome these problems and would improve treatment of malignancies.
ISSN:1093-9946
2768-6698
1093-4715
DOI:10.2741/3850